CryoPort Inc (CYRX)

[H2R]

SoS: Projected Growth

That's the part of the article that makes the most sense to me:

It is important to understand that Kymriah and Yescarta are just the first two therapies based on living cells to be approved.

There will be a tsunami of other cell based therapies that will come to market over the coming decades.

Market research cited by Cryoport projects that there could be somewhere between 56 and 129 unique new cell based therapies approved by 2027; I expect that Cryoport will support most of them.

In the near term, Cryoport said that its clients filed 7 MAAs/BLAs in 2020 and estimates they will file 23 more in 2021. An MAA/BLA can be a regulatory submission for a new product or a new indication for an existing product. Cryoport is poised for explosive growth.

https://smithonstocks.com/cryoport-cyrx-buy-72-30-kymriah-sales-are-strong-and-equity-offering-was-well-received/